<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ALCOHOL (DRINK OR INGREDIENT)" >
</DRUG>
</DRUG2>
<DESCRIPTION>Possible variations of the anticoagulating effect, with increase in case of acute intoxication or decrease in case of chronic alcoholism (increased metabolism)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ALLOPURINOL" rxcui="519">
<ATC code="M04AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the allopurinol and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ALPHA-TOCOPHEROL" rxcui="11256">
<ATC code="A11HA03" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the vitamin E used in doses greater than or equal to 500 mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with vitamin E and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="AMINOGLUTETHIMIDE" rxcui="677">
<ATC code="L02BG01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Described for warfarin and acenocoumarol.

Decrease of the effect of the vitamin K antagonist, due to increase of its hepatic metabolism by the aminoglutethimide</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with aminoglutethimide and two weeks after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the amiodorone and a week after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="ANDROGENS" code="A14AA0" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to direct effect on the coagulation and/or the fibrinolytic systems</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the androgen and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease (or, infrequently, increase with the phenytoin) of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the anticonvulsant inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the anticonvulsant inducer and a week after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="ANTIPURINES" code="ANTIPUR" /></DRUG2>
<DESCRIPTION>Decrease of the effect of the Vitamin K antagonist due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequesnt testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist at the beginning of the treatment by the immunomodulator and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="APREPITANT" rxcui="358255">
<ATC code="A04AD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the aprepitant</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during and after the administration of the medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="BOSENTAN" rxcui="75207">
<ATC code="C02KX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use </SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CEFAMANDOLE" rxcui="2178">
<ATC code="J01DC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CEFOPERAZONE" rxcui="2184">
<ATC code="J01DD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during treatment with the cephalosporin and after it is stopped </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CEFOTETAN" rxcui="2184">
<ATC code="J01DC05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution of use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CEFTRIAXONE" rxcui="2193">
<ATC code="J01DD04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cephalosporin and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CIMETIDINE" rxcui="2541">
<ATC code="A02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>With the cimetidine used in doses greater than or equal to 800mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the cimetidine and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="CLINDAMYCIN" rxcui="2582">
<ATC code="D10AF01" />
<ATC code="G01AA10" />
<ATC code="J01FF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin Kantagonist during the treatment with clindamycin and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the colchicine and a week after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="TETRACYCLINE ANTIBIOTICS" code="J01AA" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tetracycline antibiotic and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="CYTOTOXICS" code="L01" /></DRUG2>
<DESCRIPTION>Increase of the risk of thrombosis and hemorrhage accompanying tumors. In addition, possible interaction between the vitamin K antagonist and the chemotherapy</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="DANAZOL" rxcui="3102">
<ATC code="G03XA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to direct effect on coagulation and/or the fibrinolytic systems.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the danazol and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of causing ulcers and digestive hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="DISULFIRAM" rxcui="3554">
<ATC code="N07BB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the disulfiram and a week after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the dronedarone and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ECONAZOLE" rxcui="3743">
<ATC code="G01AF05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Regardless of the route of administration of the econazole:

increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with econazole and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="EFAVIRENZ" rxcui="195085">
<ATC code="J05AR06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="FIBRATES" code="C01AB-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fibrate and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="FLUCONAZOLE" rxcui="4450">
<ATC code="J02AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluconazole and a week after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="FLUOROQUINOLONES" code="J01MA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the fluoroquinolone and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)" code="L01BC-001" /></DRUG2>
<DESCRIPTION>Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If it is not possible to avoid administering these together, more frequent testing of the INR. Adjustment of the dosage of the vitamin K antagonist during the treatment with the cytotoxic and a week after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="GLUCOSAMINE" rxcui="4845">
<ATC code="M01AX05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="GRISEOFULVINE" rxcui="5021">
<ATC code="D01BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the griseofulvine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the griseofulvine and a week after it is stopped </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-003" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>When the heparin alternates with the vitamin K antagonist, strengthen clinical monitoring. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="IMATINIB" rxcui="282388">
<ATC code="L01XE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering these together cannot be avoided, strict clinical monitoring and more frequent monitoring of the INR</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="HMG-COA REDUCTASE INHIBITORS (STATINS)" code="C10AA" /></DRUG2>
<DESCRIPTION>Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the Vitamin K antagonist.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Variation of the effect of the vitamin K antagonist, most often by decreasing it</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the length of the treatment</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the itraconazole and a week after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="LEVOCARNITINE" rxcui="42955">
<ATC code="A16AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequenttesting of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with levocarnitine and a week after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="MACROLIDES (EXCEPT SPIRAMYCIN)" code="J01FA" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage the vitamin K antagonist during the treatment with the macrolide and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="METHYLPREDNISOLONE " rxcui="6902">
<ATC code="D07AA01" />
<ATC code="D10AA02" />
<ATC code="H02AB04" />
<ATC code="D07CA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>For doses of 0.5g to 1g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Testing of the INR 2 to 4 days after the bolus of mythylprednisolone or in the presence of any signs of hemorrhage</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="MICONAZOLE " rxcui="6932">
<ATC code="A01AB09" />
<ATC code="A07AC01" />
<ATC code="D01AC02" />
<ATC code="G01AF04" />
<ATC code="J02AB01" />
<ATC code="S02AA13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Unpredictable hemorrhage, possibly serious</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ST JOHN'S WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the vitamin K antagonist, by reason of its enzyme inducer effect, with risk of reduction of effectiveness, even complete loss of the effect, which could have serious consequences (thrombolitic event)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>In case of an accidental use of the two substances together, do not stop the St Johns Wort suddenly, but test the INR before and then after the St Johns Wort is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE " rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR Possible adjustment of the dosage of the vitamin K antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="NOSCAPINE" rxcui="7533">
<ATC code="R05DA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the orlistat and after it is stopped </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="PARACETAMOL" rxcui="161">
<ATC code="N02BE01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during treatment with the paracetamol and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="PENTOXIFYLLINE" rxcui="8013">
<ATC code="C04AD03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pentoxifylline and a week after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="PRISTINAMYCIN" rxcui="66958">
<ATC code="J01FG01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the pristinamycin and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="PROGUANIL" rxcui="2382">
<ATC code="P01BB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the proguanil and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the anticoagulant effect and of the risk of hemorrhage. Mecanism proposed: inhibition of the metabolism of the vitamin K antagonist</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the propafenone and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the rifampicin and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="ROPINIROLE" rxcui="72302">
<ATC code="N04BC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with ropinirole and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="SUCRALFATE" rxcui="10156">
<ATC code="A02BX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digestive absorption of the vitamin K antagonist</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Take the sucralfate at a different time from the vitamin K antagonist (more than 2 hours apart, if possible)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="SULFAFURAZOLE" rxcui="10207">
<ATC code="S01AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the antibiotic and a week after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="SULFAMETHIZOLE" rxcui="10179">
<ATC code="B05CA04" />
<ATC code="D06BA04" />
<ATC code="J01EB02" />
<ATC code="S01AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the antibiotic treatment and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="SULFAMETHOXAZOLE" rxcui="10180">
<ATC code="J01EC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage </DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, more frequent testing of the INR and adjustment of the dosage of the vitamin K antagonist during the treatment with cotrimoxazole and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="TIBOLONE" rxcui="38260">
<ATC code="G03CX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tibolone and after it is stopped</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="TRAMADOL" rxcui="10689">
<ATC code="N02AX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the tramadol and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>72-VITAMIN-K-ANTAGONISTS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage due to decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with voriconazole and a week after it is stopped. </COMMENT>
</INTERACTION>
</INTERACTIONS>
